Literature DB >> 23911305

Delivery and processing of exogenous double-stranded DNA in mouse CD34+ hematopoietic progenitor cells and their cell cycle changes upon combined treatment with cyclophosphamide and double-stranded DNA.

Evgenia V Dolgova1, Yaroslav R Efremov, Konstantin E Orishchenko, Oleg M Andrushkevich, Ekaterina A Alyamkina, Anastasia S Proskurina, Sergey I Bayborodin, Valeriy P Nikolin, Nelly A Popova, Elena R Chernykh, Alexandr A Ostanin, Oleg S Taranov, Vladimir V Omigov, Alexandra M Minkevich, Vladimir A Rogachev, Sergey S Bogachev, Mikhail A Shurdov.   

Abstract

We previously reported that fragments of exogenous double-stranded DNA can be internalized by mouse bone marrow cells without any transfection. Our present analysis shows that only 2% of bone marrow cells take up the fragments of extracellular exogenous DNA. Of these, ~45% of the cells correspond to CD34+ hematopoietic stem cells. Taking into account that CD34+ stem cells constituted 2.5% of the total cell population in the bone marrow samples analyzed, these data indicate that as much as 40% of CD34+ cells readily internalize fragments of extracellular exogenous DNA. This suggests that internalization of fragmented dsDNA is a general feature of poorly differentiated cells, in particular CD34+ bone marrow cells. When linearized plasmid DNA was used as a source of exogenous DNA, we observed that exonucleolytic processing and ligation of double-stranded DNA termini occurred in the bone marrow cells that had this DNA internalized. We also recovered "hybrid" plasmids that encompass kanamycin-resistance gene from the exogenous plasmid DNA and the fragments of plasmids from host enterobacteria, which is suggestive of recombination events taking place upon DNA internalization. CD34+ cells make up the distinctive bone marrow cell population that internalizes extracellular DNA. Cell cycle analysis of CD34+ cells treated with cyclophosphamide only or in combination with dsDNA, suggests that these cells have distinct biologic responses to these treatments. Namely, whereas upon cyclophosphamide treatment bone marrow stem cells become arrested at S-G2 phases, combined cyclophosphamide+dsDNA treatment leads to cell cycle progression without any delay. This indicates that when the genome is undergoing repair of interstrand crosslinks, injection of fragmented exogenous dsDNA results in immediate reconstitution of genome integrity. We observe that cyclophosphamide-only or a combined cyclophosphamide+dsDNA treatment of cells lead to two distinct waves of apoptosis in CD34+ progenitors. We also show that cyclophosphamide and cyclophosphamide+dsDNA injections promote division of CD34+ cells at distinct time periods.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; BMCs; Bone marrow stem cells; CD34+; CP; Cell cycle; DSB; Double-stranded DNA; Enterobacteria; HSCs; ICL; bone marrow cells; cyclophosphamide; double-stranded DNA; double-stranded break; dsDNA; hematopoietic stem cells; interstrand cross-link

Mesh:

Substances:

Year:  2013        PMID: 23911305     DOI: 10.1016/j.gene.2013.06.058

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

1.  Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells.

Authors:  Ekaterina A Potter; Evgenia V Dolgova; Anastasia S Proskurina; Yaroslav R Efremov; Alexandra M Minkevich; Aleksey S Rozanov; Sergey E Peltek; Valeriy P Nikolin; Nelly A Popova; Igor A Seledtsov; Vladimir V Molodtsov; Evgeniy L Zavyalov; Oleg S Taranov; Sergey I Baiborodin; Alexander A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2017-02-07

2.  Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model.

Authors:  Vera Ruzanova; Anastasia Proskurina; Yaroslav Efremov; Svetlana Kirikovich; Genrikh Ritter; Evgenii Levites; Evgenia Dolgova; Ekaterina Potter; Oksana Babaeva; Sergey Sidorov; Oleg Taranov; Alexandr Ostanin; Elena Chernykh; Sergey Bogachev
Journal:  Pathol Oncol Res       Date:  2022-05-27       Impact factor: 2.874

3.  Combination of cyclophosphamide and double-stranded DNA demonstrates synergistic toxicity against established xenografts.

Authors:  Ekaterina A Alyamkina; Valeriy P Nikolin; Nelly A Popova; Alexandra M Minkevich; Artem V Kozel; Evgenia V Dolgova; Yaroslav R Efremov; Sergey I Bayborodin; Oleg M Andrushkevich; Oleg S Taranov; Vladimir V Omigov; Vladimir A Rogachev; Anastasia S Proskurina; Evgeniy I Vereschagin; Elena V Kiseleva; Maria V Zhukova; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev; Mikhail A Shurdov
Journal:  Cancer Cell Int       Date:  2015-03-19       Impact factor: 5.722

4.  Identification of cancer stem cells and a strategy for their elimination.

Authors:  Evgenia V Dolgova; Ekaterina A Alyamkina; Yaroslav R Efremov; Valeriy P Nikolin; Nelly A Popova; Tamara V Tyrinova; Artem V Kozel; Alexandra M Minkevich; Oleg M Andrushkevich; Evgeniy L Zavyalov; Alexander V Romaschenko; Sergey I Bayborodin; Oleg S Taranov; Vladimir V Omigov; Ekaterina Ya Shevela; Vyacheslav V Stupak; Sergey V Mishinov; Vladimir A Rogachev; Anastasia S Proskurina; Vladimir I Mayorov; Mikhail A Shurdov; Alexander A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Cancer Biol Ther       Date:  2014-10       Impact factor: 4.742

5.  Properties of internalization factors contributing to the uptake of extracellular DNA into tumor-initiating stem cells of mouse Krebs-2 cell line.

Authors:  Evgeniya V Dolgova; Ekaterina A Potter; Anastasiya S Proskurina; Alexandra M Minkevich; Elena R Chernych; Alexandr A Ostanin; Yaroslav R Efremov; Sergey I Bayborodin; Valeriy P Nikolin; Nelly A Popova; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Stem Cell Res Ther       Date:  2016-05-25       Impact factor: 6.832

6.  A strategy to eradicate well-developed Krebs-2 ascites in mice.

Authors:  Ekaterina A Potter; Evgenia V Dolgova; Anastasia S Proskurina; Alexandra M Minkevich; Yaroslav R Efremov; Oleg S Taranov; Vladimir V Omigov; Valeriy P Nikolin; Nelly A Popova; Sergey I Bayborodin; Alexander A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Mikhail A Shurdov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2016-03-08

7.  Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.

Authors:  Anastasia S Proskurina; Tatiana S Gvozdeva; Ekaterina A Potter; Evgenia V Dolgova; Konstantin E Orishchenko; Valeriy P Nikolin; Nelly A Popova; Sergey V Sidorov; Elena R Chernykh; Alexandr A Ostanin; Olga Y Leplina; Victoria V Dvornichenko; Dmitriy M Ponomarenko; Galina S Soldatova; Nikolay A Varaksin; Tatiana G Ryabicheva; Peter N Uchakin; Vladimir A Rogachev; Mikhail A Shurdov; Sergey S Bogachev
Journal:  BMC Cancer       Date:  2016-08-18       Impact factor: 4.430

8.  P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions.

Authors:  Tatiana Halenova; Oleksii Savchuk; Ludmila Ostapchenko; Andrey Chursov; Nathan Fridlyand; Andrey B Komissarov; Franco Venanzi; Sergey I Kolesnikov; Albert A Sufianov; Michael Y Sherman; Vladimir L Gabai; Alexander M Shneider
Journal:  Oncotarget       Date:  2017-08-03

9.  Efficacy of a new cancer treatment strategy based on eradication of tumor-initiating stem cells in a mouse model of Krebs-2 solid adenocarcinoma.

Authors:  Ekaterina A Potter; Anastasia S Proskurina; Genrikh S Ritter; Evgenia V Dolgova; Valeriy P Nikolin; Nelly A Popova; Oleg S Taranov; Yaroslav R Efremov; Sergey I Bayborodin; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Oncotarget       Date:  2018-06-19

10.  Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas.

Authors:  Evgeniya V Dolgova; Sergey V Mishinov; Anastasiya S Proskurina; Ekaterina A Potter; Yaroslav R Efremov; Sergey I Bayborodin; Tamara V Tyrinova; Vyacheslav V Stupak; Alexandr A Ostatin; Elena R Chernykh; Sergey S Bogachev
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.